- Home
- CURR vs SKYE Comparison
CURR vs SKYE Comparison
Compare CURR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- SKYE
- Stock Information
- Founded
- CURR 2013
- SKYE 2012
- Country
- CURR Singapore
- SKYE United States
- Employees
- CURR N/A
- SKYE N/A
- Industry
- CURR Business Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- CURR Consumer Discretionary
- SKYE Health Care
- Exchange
- CURR Nasdaq
- SKYE Nasdaq
- Market Cap
- CURR 74.0M
- SKYE 80.7M
- IPO Year
- CURR N/A
- SKYE N/A
- Fundamental
- Price
- CURR $0.62
- SKYE $2.06
- Analyst Decision
- CURR Strong Buy
- SKYE Buy
- Analyst Count
- CURR 1
- SKYE 6
- Target Price
- CURR $3.50
- SKYE $16.60
- AVG Volume (30 Days)
- CURR 2.0M
- SKYE 223.6K
- Earning Date
- CURR 05-20-2025
- SKYE 05-08-2025
- Dividend Yield
- CURR N/A
- SKYE N/A
- EPS Growth
- CURR N/A
- SKYE N/A
- EPS
- CURR N/A
- SKYE N/A
- Revenue
- CURR $43,386,858.00
- SKYE N/A
- Revenue This Year
- CURR N/A
- SKYE N/A
- Revenue Next Year
- CURR $17.98
- SKYE N/A
- P/E Ratio
- CURR N/A
- SKYE N/A
- Revenue Growth
- CURR N/A
- SKYE N/A
- 52 Week Low
- CURR $0.44
- SKYE $1.14
- 52 Week High
- CURR $7.08
- SKYE $12.11
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- SKYE 51.05
- Support Level
- CURR N/A
- SKYE $1.96
- Resistance Level
- CURR N/A
- SKYE $2.28
- Average True Range (ATR)
- CURR 0.00
- SKYE 0.22
- MACD
- CURR 0.00
- SKYE -0.00
- Stochastic Oscillator
- CURR 0.00
- SKYE 47.00
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.